Regeneron Director Christine Poon Files Form 144 to Sell $7.53M in Common Stock
REGENERON PHARMACEUTICALS, INC.
Subscribe to track REGN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📢 Form 144 Filing Alert: Regeneron Pharmaceuticals, Inc. ($REGN) • Insider: Christine Poon (Director) • Proposed Sale: 7,830 shares ($7,526,666 est. value) • Approx. Sale Date: 11/02/2026 • Broker: Goldman Sachs & Co. LLC • Source: Option exercises (Cashless exercise / same-day sale)
Comprehensive Analysis
Regeneron Pharmaceuticals ($REGN) Form 144 Analysis
Overview:
On November 2, 2026, Regeneron Pharmaceuticals, Inc. director Christine Poon submitted a Form 144 notice disclosing the proposed sale of 7,830 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of approximately $7.53 million (~$961.26 per share).
Origin of Shares:
The securities are derived from stock option exercises originally granted as compensation across three equal tranches of 2,610 shares acquired on January 3, 2018, January 3, 2019, and January 3, 2020. The transaction involves a cashless exercise and same-day sale.
Market & Dilution Impact:
- Shares to be Sold: 7,830
- Shares Outstanding: 101,630,713
- Relative Size: Approximately 0.0077% of outstanding shares
Given that the transaction represents routine monetization of expiring or vested director compensation via a cashless exercise, market impact is anticipated to be negligible.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.